Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | LDHB | P07195 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24743202 | 1.00 | LDHA (0.34) | LDHALDHBPPARDPPARGPPARA | |
| SCHEMBL1033622 | 0.90 | PPARD (0.42) | LDHALDHBPPARDPPARGPPARA | |
| SCHEMBL1031012 | 0.88 | PPARD (0.35) | LDHALDHBPPARDPPARGPPARA | |
| SCHEMBL1035053 | 0.86 | BCL2L1 (0.35) | LDHALDHBHSD11B1 | |
| SCHEMBL30003789 | 0.82 | DAO (0.32) | LDHALDHBDAO | |
| SCHEMBL24742599 | 0.82 | DAO (0.32) | LDHALDHBDAO | |
| SCHEMBL1035016 | 0.81 | PPARD (0.41) | LDHALDHBPPARDPPARGPPARA | |
| SCHEMBL1031604 | 0.81 | PPARD (0.45) | PPARDPPARGPPARA | |
| SCHEMBL1033215 | 0.80 | PPARD (0.40) | LDHALDHBPPARDPPARGPPARA | |
| SCHEMBL27988156 | 0.80 | PTGDR2 (0.34) | LDHALDHBPPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333379-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12297168-B2 | Compounds useful for treating liver diseases | ABIONYX PHARMA SA (FR) | 2025-05-13 | — | — | US | disclosed |
| US-20240199575-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2024-06-20 | — | — | US | disclosed |
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2023-09-07 | — | — | US | disclosed |
| US-11634387-B2 | Compounds useful for treating liver diseases | ABIONYX PHARMA SA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | ABIONYX PHARMA SA (FR) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278952-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | LDHA 510/4885LDHB 679/4885PPARD 332/4885 |
| US-20240199575-A1 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | SLC10A1, FABP1, CPT1A | LDHA 510/4885LDHB 679/4885PPARD 332/4885 |
| US-11634387-B2 | Compounds useful for treating liver diseases | SLC10A1, FABP1, CPT1A | LDHA 510/4885LDHB 679/4885PPARD 332/4885 |
| US-20250333379-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | LDHA 510/4885LDHB 679/4885PPARD 332/4885 |
| US-12297168-B2 | Compounds useful for treating liver diseases | SLC10A1, FABP1, CPT1A | LDHA 510/4885LDHB 679/4885PPARD 332/4885 |
| US-20220363632-A1 | Compounds Useful for Treating Liver Diseases | SLC10A1, FABP1, CPT1A | LDHA 510/4885LDHB 679/4885PPARD 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.